Inhibition of Cpeb3 ribozyme elevates CPEB3 protein expression and polyadenylation of its target mRNAs, and enhances object location memory

  1. Claire C Chen
  2. Joseph Han
  3. Carlene A Chinn
  4. Jacob S Rounds
  5. Xiang Li
  6. Mehran Nikan
  7. Marie Myszka
  8. Liqi Tong
  9. Luiz F M Passalacqua
  10. Timothy Bredy
  11. Marcelo A Wood  Is a corresponding author
  12. Andrej Luptak  Is a corresponding author
  1. University of California, Irvine, United States
  2. University of Queensland, Australia
  3. Ionis Pharmaceuticals, United States

Abstract

A self-cleaving ribozyme that maps to an intron of the cytoplasmic polyadenylation element binding protein 3 (Cpeb3) gene is thought to play a role in human episodic memory, but the underlying mechanisms mediating this effect are not known. We tested the activity of the murine sequence and found that the ribozyme’s self-scission half-life matches the time it takes an RNA polymerase to reach the immediate downstream exon, suggesting that the ribozyme-dependent intron cleavage is tuned to co-transcriptional splicing of the Cpeb3 mRNA. Our studies also reveal that the murine ribozyme modulates maturation of its harboring mRNA in both cultured cortical neurons and the hippocampus: inhibition of the ribozyme using an antisense oligonucleotide leads to increased CPEB3 protein expression, which enhances polyadenylation and translation of localized plasticity-related target mRNAs, and subsequently strengthens hippocampal-dependent long-term memory. These findings reveal a previously unknown role for self-cleaving ribozyme activity in regulating experience-induced co-transcriptional and local translational processes required for learning and memory.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1 - 7.

Article and author information

Author details

  1. Claire C Chen

    Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  2. Joseph Han

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  3. Carlene A Chinn

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  4. Jacob S Rounds

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  5. Xiang Li

    Queensland Brain Institute, University of Queensland, Brisbane, Australia
    Competing interests
    No competing interests declared.
  6. Mehran Nikan

    Ionis Pharmaceuticals, Carlsbad, United States
    Competing interests
    Mehran Nikan, Mehran Nikan is affiliated with Ionis Pharmaceuticals. The author has no financial interests to declare..
  7. Marie Myszka

    Department of Chemistry, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  8. Liqi Tong

    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  9. Luiz F M Passalacqua

    Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5490-2427
  10. Timothy Bredy

    Queensland Brain Institute, University of Queensland, Brisbane, Australia
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3280-126X
  11. Marcelo A Wood

    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States
    For correspondence
    mwood@uci.edu
    Competing interests
    No competing interests declared.
  12. Andrej Luptak

    Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, United States
    For correspondence
    aluptak@uci.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0632-5442

Funding

National Institutes of Health (R01AG051807)

  • Marcelo A Wood

National Institutes of Health (RF1AG057558)

  • Marcelo A Wood

National Science Foundation (1804220)

  • Andrej Luptak

National Science Foundation (1330606)

  • Andrej Luptak

National Science Foundation Graduate Research Fellowship Program

  • Claire C Chen

National Institutes of Health (R01CA229696)

  • Claire C Chen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experimental procedures were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the University of California, Irvine.

Copyright

© 2024, Chen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 776
    views
  • 113
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Claire C Chen
  2. Joseph Han
  3. Carlene A Chinn
  4. Jacob S Rounds
  5. Xiang Li
  6. Mehran Nikan
  7. Marie Myszka
  8. Liqi Tong
  9. Luiz F M Passalacqua
  10. Timothy Bredy
  11. Marcelo A Wood
  12. Andrej Luptak
(2024)
Inhibition of Cpeb3 ribozyme elevates CPEB3 protein expression and polyadenylation of its target mRNAs, and enhances object location memory
eLife 13:e90116.
https://doi.org/10.7554/eLife.90116

Share this article

https://doi.org/10.7554/eLife.90116

Further reading

    1. Chromosomes and Gene Expression
    2. Microbiology and Infectious Disease
    Maruti Nandan Rai, Qing Lan ... Koon Ho Wong
    Research Article Updated

    Candida glabrata can thrive inside macrophages and tolerate high levels of azole antifungals. These innate abilities render infections by this human pathogen a clinical challenge. How C. glabrata reacts inside macrophages and what is the molecular basis of its drug tolerance are not well understood. Here, we mapped genome-wide RNA polymerase II (RNAPII) occupancy in C. glabrata to delineate its transcriptional responses during macrophage infection in high temporal resolution. RNAPII profiles revealed dynamic C. glabrata responses to macrophages with genes of specialized pathways activated chronologically at different times of infection. We identified an uncharacterized transcription factor (CgXbp1) important for the chronological macrophage response, survival in macrophages, and virulence. Genome-wide mapping of CgXbp1 direct targets further revealed its multi-faceted functions, regulating not only virulence-related genes but also genes associated with drug resistance. Finally, we showed that CgXbp1 indeed also affects fluconazole resistance. Overall, this work presents a powerful approach for examining host-pathogen interaction and uncovers a novel transcription factor important for C. glabrata’s survival in macrophages and drug tolerance.

    1. Chromosomes and Gene Expression
    2. Neuroscience
    Robyn D Moir, Emilio Merheb ... Ian M Willis
    Research Article

    Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.